NEW DELHI: Call it the flu effect. Domestic pharma retail market posted a robust 11% growth in July, buoyed by sales of ...

Orthogon Therapeutics, a privately held research and development (R&D) company, uses principles of biophysics and structure-based drug design to develop anti-infective small molecules that ...

Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix ...

Global strategies to contain the spread of AMR include a coordinated surveillance network and the development of novel classes of anti-infectives. In June 2021, the WHO released its fourth Global ...

Basilea Pharmaceutica (SIX: BSLN) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of ...

Last year, GSK said it was planning to invest a cool £1 billion in infectious diseases, with an emphasis on neglected tropical diseases and antimicrobial resistance (AMR). Now, its spent some of ...

Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations.

Shares of Zoetis ZTS have risen 15.4% in the past three months compared with the industry’s 9.3% growth. The stock has also ...

Find insight on GSK and more in the latest Market Talks covering the Health Care sector.

Cidara Therapeutics (CDTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

In July, India's domestic pharma retail market experienced an 11% growth, driven by sales of anti-infectives and pain-relief medicines due to increased flu and viral infections. Augmentin emerged ...